It is worth noting that cancer cells have diverse capacities to utilize inosine, and supplementation with inosine or PEG–ADA enhances the potency and durability of T-cell-based cancer immunotherapy in several solid tumor models, such as melanoma and neuroblastoma. Here, ADA is linked to cancer.